Archive
Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024
Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in...
Azenta Announces the Election of Dipal Doshi to its Board of Directors
Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical...
Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a...
UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence
Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of...
Azenta to Participate in Stephens Annual Investment Conference
Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation...
Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO
FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA...
Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company...
Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board...
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain...
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen...